<article id="leonard_2009_p" class="slide" data-ag-slide-name="Leonard 2009 (P)">
    <div class="basic">
      <h1 id="leonard_2009_header" data-ag-editable="Leonard 2009 (P) Main Title">Neulasta<sup>®</sup> allows you to achieve ≥85% of relative dose intensity (RDI) of chemotherapy for over 85% of your breast cancer patients even after they have experienced a neutropenic event<sup>1</sup></h1>
      <div id="rdi_page2_top_p">
         <p class="red_subtitle2" id="leonard_2009_subheader" data-ag-editable="Leonard 2009 (P) Top Copy">Being unable to deliver the relative dose intensity (RDI) of ≥85% in adjuvant chemotherapy reduces the likelihood of 10-year survival in breast cancer<sup>2</sup></p>
      </div>
      <div id="rdi_page2_data_holder_p">
         <ul class="red_dot_list" data-ag-editable="Leonard 2009 (P) Left List Copy">
            <li>In a prospective study, 407 patients with early stage breast cancer receiving standard dose adjuvant chemotherapy were randomised at first neutropenia event<sup>*</sup> to management with dose delays or dose reductions versus G-CSF as secondary prophylaxis<sup>1</sup></li>
            <li>After initiation of G-CSF, patients continued to receive G-CSF throughout all cycles</li>
         </ul>
         <div id="rdi_page2_graph1_p" class="main_content_style">
            <img src="content/images/pragmatist_pages/rdi/rdi_page2_graph1_bg.png" width="433" height="359" data-ag-editable="Leonard 2009 (P) Graph Background" />
             <div id="leonard_2009_p_graph_content"  data-ag-editable="Leonard 2009 (P) Graph Content">
                 <h2 id="graph_header">Proportion of patients achieving RDI ≥85%</h2>
                 <p id="graph_vertical_axis_title">Proportion of patients achieving RDI ≥85%</p>
                 <p id="graph_horizontal_axis_title1">No G-CSF</p>
                 <p id="graph_horizontal_axis_title2">Daily Filgrastim</p>
                 <p id="graph_horizontal_axis_title3">Neulasta<sup>®</sup></p>
                 <p id="graph_bottom_text">Adapted from Leonard R <span class="et_al">et al.</span> J Cancer Suppl 2009; 7(2);270</p>
                 <p id="graph_arrow1_value">45</p>
                 <p id="graph_arrow2_value">70,7</p>
                 <p id="graph_arrow3_value">85,1</p>
             </div>
            <div id="rdi_page2_graph1_arrow1_p">
               <img src="content/images/pragmatist_pages/rdi/rdi_page2_graph1_arrow1.png" width="82" height="119" data-ag-editable="Leonard 2009 (P) Graph Bar 1" />
            </div>
            <div id="rdi_page2_graph1_arrow2_p">
               <img src="content/images/pragmatist_pages/rdi/rdi_page2_graph1_arrow2.png" width="82" height="183" data-ag-editable="Leonard 2009 (P) Graph Bar 2" />
            </div>
            <div id="rdi_page2_graph1_arrow3_p">
               <img src="content/images/pragmatist_pages/rdi/rdi_page2_graph1_arrow3.png" width="82" height="221" data-ag-editable="Leonard 2009 (P) Graph Bar 3" />
            </div>
         </div>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="enlarge_graph" id="enlarge_graph_leonard_2009_p"></div>
    <div class="lightbox_data" id="leonard_2009_p_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Leonard 2009 (P) References Title">References:</strong></p>
          <div data-ag-editable="Leonard 2009 (P) References List">
             <ol>
                <li>Leonard R <em>et al</em>. Secondary PROphylaxis with G-CSF has a major effect on delivered dose intensity: The results of the UK NCRI/Anglo Celtic SPROG trial for adjuvant chemotherapy of breast cancer. Eur J Cancer Suppl 2009; 7(2):270</li>
                <li>Chirivella L <em>et al</em>. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009; 114(3):479-484</li>
             </ol>
          </div>
          <p data-ag-editable="Leonard 2009 (P) References Bottom Copy">* Absolute neutrophil count &lt;1000 /mm<sup>3</sup> or neutropenic fever</p>
       </div>
    </div>
    <!-- Reference Information Ends -->
    <div class="large_graph_container">
            <div id="leonard_2009_p_large" class="large_graph">
              <div class="large_style">
               <img src="content/images/pragmatist_pages/rdi/page2_graph_large.png" width="807" height="535" data-ag-editable="Leonard 2009 Prag Large Graph" />
                  <div id="leonard_2009_p_graph_content_large" data-ag-editable="Leonard 2009 (P) Graph Content">
                      <h2 id="graph_header_large">Proportion of patients achieving RDI ≥85%</h2>
                      <p id="graph_vertical_axis_title_large">Proportion of patients achieving RDI ≥85%</p>
                      <p id="graph_horizontal_axis_title1_large">No G-CSF</p>
                      <p id="graph_horizontal_axis_title2_large">Daily Filgrastim</p>
                      <p id="graph_horizontal_axis_title3_large">Neulasta<sup>®</sup></p>
                      <p id="graph_bottom_text_large">Adapted from Leonard R <span class="et_al">et al.</span> J Cancer Suppl 2009; 7(2);270</p>
                      <p id="graph_arrow1_value_large">45</p>
                      <p id="graph_arrow2_value_large">70,7</p>
                      <p id="graph_arrow3_value_large">85,1</p>
                  </div>
               </div>
            </div>
    </div>
</article>